Background
==========

Antimicrobial resistance has emerged as an important factor in predicting outcomes and overall resource use after infections in intensive care units (ICU) \[[@B1]\]. Globally ICUs are encountering emergence and spread of antibiotic-resistant pathogens. For some pathogens there are few therapeutic options available, e.g., vancomycin-resistant *Enterococcus faecium*. Awareness of these problems has been underscored with data from a number of surveillance studies aimed at improving the use of empiric therapy. In the United States there have been several national programs, which have focused on both the etiology of infections and resistance patterns of nosocomial or ICU infections including the National Nosocomial Infections Surveillance (NNIS) \[[@B2]\] and more recently an ICU-specific study examining the epidemiology of antimicrobial resistance, Project ICARE \[[@B3],[@B4]\]. Stephen et al. collected strains from 28 ICUs from across the United States as part of the SENTRY Antimicrobial Surveillance Program in 2001 \[[@B5]\].

European data on the antimicrobial resistance of ICU pathogens has also been collected in several recent surveillance studies. A large prevalence survey of nosocomial infections in ICUs in 17 countries was published in 1995 \[[@B6]\], and more recently a number of nation-specific surveys were reported \[[@B7]-[@B9]\]. Several key points emerge: first, antimicrobial resistance among ICU pathogens is generally increasing, but variations do exist among different countries, probably due to individual antimicrobial use patterns; second, when new medical practices and alternative antimicrobials are introduced changes in the dominant microbial etiologies may emerge prompting novel empiric selections; and third, the standards of hygiene and infection control also vary across countries. Finally, appropriate therapy of ICU infections directed by local resistance data can have significant consequences for both patient and the healthcare system. It is against this background that local resistance surveillance programs are of most value in developing appropriate therapeutic guidelines for specific infections and patient types. For example, the recent modification to the American Thoracic Society guidelines for the treatment of hospital-acquired pneumonia \[[@B10]\] considered contemporary resistance data. Local surveillance data can be applied to other infections to assist in local formulary policy such as those governing treatment of nosocomial urinary tract infections \[[@B11]\].

This study using TSN program reports the antimicrobial resistance profiles of bacterial isolates from ICU patients in five countries during the period 2000--2002. The relevance of these recent nation-specific data will be discussed on a country-by-country basis, as part of improving and updating empiric therapeutic approaches to specific pathogens causing infections in the ICU setting according to each country. These surveillance programs help to maintain current knowledge of susceptibilities and relevant treatment options.

Methods
=======

TSN Database -- United States and Europe
----------------------------------------

TSN is a queriable, real-time database that electronically assimilates daily antimicrobial susceptibility testing and patient demographic data from a network of geographically dispersed laboratories in the United States (283 hospital sites), France (63 hospital sites), Germany (169 hospital sites), Italy (48 hospital sites) and Canada (87 hospital sites) \[[@B12]\].

Laboratories included in TSN include those servicing university, community, and private hospitals with bed sizes ranging from 100 to \>1000 beds. Routine diagnostic susceptibility testing results are collected daily from each participating laboratory. The methods used by these laboratories include VITEK (bioMérieux, St. Louis, MO), MicroScan (Dade-Microscan, Sacramento, CA), Sceptor and Pasco MIC/ID (Becton Dickinson, Sparks, MD) and Etest (AB Biodisk, Solna, Sweden), as well as manual broth microdilution MIC, disk diffusion and agar dilution. TSN reflects current testing in participant laboratories and represents the data reported to physicians from the respective laboratories \[[@B13]\].

Although some European countries have alternate breakpoints, all data forwarded to TSN Databases are derived from hospitals that utilized NCCLS standards and definitions (United States, Canada, Italy, and Germany) \[[@B14]\] or the Comité de L\'Antibiogramme de La Societé Français de Microbiologie (France) \[[@B15]\] thus standardizing datasets. Results were interpreted as susceptible, intermediate (if available), or resistant in TSN, based upon the NCCLS interpretative guidelines in place during 2001 \[[@B16]\]. In addition, a series of quality-control filters (i.e., critical rule sets) were used in TSN to screen susceptibility test results for patterns indicative of testing error and suspect results were removed from analysis for laboratory confirmation. In TSN, any result from the same patient with the same organism identification and the same susceptibility pattern received within five days was considered a repeat culture and was counted only once in the database.

Bacterial species and antimicrobials tested
-------------------------------------------

For this study, data from TSN results for each individual database from January 1, 2000 through to December 31, 2002 were included in the analysis to determine the proportion of species and their susceptibility to antimicrobial agents commonly tested in clinical laboratories throughout the participating regions. Only isolates derived from patients located in hospital ICUs were considered in the analysis. Gram-positive species included in the analysis were comprised of *S. aureus*, coagulase negative staphylococci, *Enterococcus faecalis*,*Enterococcus faecium*, *Streptococcus pyogenes*, *Streptococcus pneumoniae* and viridans group streptococci. Gram-negative species studied comprised the predominantly encountered enteric species (*Escherichia coli*, *Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii* and *Serratia marcescens*), and *Pseudomonas aeruginosa* and *Acinetobacter* spp.

The antibiotics studied are listed in Tables [2](#T2){ref-type="table"},[3](#T3){ref-type="table"},[4](#T4){ref-type="table"},[5](#T5){ref-type="table"}. Among *E. coli*, putative ESBL production was defined as those isolates that were intermediate or resistant (non-susceptible) to ceftazidime \[[@B17]\]. Given the large number of isolate results included in the majority of analyses in this study, statistical analysis was not performed, as even subtle differences in percent resistance (\<1%) to an antimicrobial agent for any time period or demographic parameters would be reported as highly significant (*P* \<0.001).

###### 

*S. aureus*, Coagulase-negative staphylococci, *E. faecalis*, and *E. faecium* isolated from ICU patients during 2000--2002

                                                                          United States   Canada   Italy   Germany   France^a^                                                                         
  --------------------------------------------- ------------------------- --------------- -------- ------- --------- ----------- ------ ------- ------ ------ ------- ------ ------ -------- --------- ------
  *Staphylococcus aureus*                       Ampicillin                19,703          6.7      93.3    3,792     12.6        87.4   1,665   5.6    94.4   2,867   16.2   83.8   15       6.7       93.3
                                                Cefepime                  1,260           52.9     46.9    NT^b^     NT          NT     304     15.8   84.2   483     80.5   17.0   \<10     NA^c\>^   NA
                                                Cefotaxime                6,898           50.2     49.7    220       55.5        44.5   671     36.4   63.6   729     92.0   8.0    490      63.9      36.1
                                                Ceftriaxone               5,914           45.6     54.3    153       69.3        30.7   1,048   28.1   71.8   220     88.6   11.4   23       73.9      26.1
                                                Ciprofloxacin             24,350          47.4     51.0    5,958     74.5        24.1   4,600   39.7   58.6   5,243   73.4   26.1   316      57.0      40.5
                                                Gentamicin                35,034          85.6     13.7    6,641     89.4        10.3   5,531   40.9   58.0   5,735   90.0   9.7    10,100   90.4      9.4
                                                Oxacillin                 44,939          47.7     52.3    10,105    80.3        19.7   6,147   40.6   59.4   6,475   79.0   21.0   10,512   59.4      40.6
                                                Teicoplanin               NT              NT       NT      NT        NT          NT     5,868   100    0      4,632   99.8   0.2    8,232    100       0
                                                Vancomycin                43,245          100      0       7,882     100         0      5,937   100    0      5,276   100    0      9,453    100       0
  *Staphylococcus aureus*                                                                                                                                                                              
  OSSA                                          Ampicillin                9,047           14.5     85.5    3,055     15.7        84.3   741     12.6   87.4   2,414   19.3   80.7   10       0         100
                                                Cefepime                  672             99.1     0.4     NT        NT          NT     49      98.0   2.0    387     99.5   0.3    NT       NT        NT
                                                Cefotaxime                3,451           99.7     0.2     122       100         0      244     100    0      653     100    0      312      100       0
                                                Ceftriaxone               2,707           99.5     0.2     106       100         0      295     99.0   0.3    194     100    0      16       100       0
                                                Ciprofloxacin             11,827          91.2     6.5     4,692     93.5        4.8    1,902   91.4   4.9    4,171   91.4   8.0    188      90.4      6.4
                                                Gentamicin                16,951          98.3     1.4     5,384     98.1        1.8    2,223   95.1   4.5    4,527   98.4   1.5    5,958    99.4      0.5
                                                Oxacillin                 21,416          100      0       8,110     100         0      2,495   100    0      5,115   100    0      6,244    100       0
                                                Teicoplanin               NT              NT       NT      NT        NT          NT     2,402   100    0      3,593   99.9   0.1    5,018    100       0
                                                Vancomycin                20,110          100      0       6,046     100         0      2,430   100    0      4,002   100    0      5,580    100       0
  *Staphylococcus aureus*                                                                                                                                                                              
  ORSA                                          Ampicillin                10,656          0        100     737       0           100    924     0      100    453     0      100    \<10     NA        NA
                                                Cefepime                  588             0        100     NT        NT          NT     255     0      100    96      4.2    84.4   \<10     NA        NA
                                                Cefotaxime                3,447           0.6      99.3    98        0           100    427     0      100    76      23.7   76.3   178      0.6       99.4
                                                Ceftriaxone               3,207           0        100     47        0           100    753     0.3    99.7   26      3.8    96.2   \<10     NA        NA
                                                Ciprofloxacin             12,523          6.1      93.1    1,266     3.9         95.5   2,698   3.3    96.4   1,072   3.3    96.6   128      7.8       90.6
                                                Gentamicin                18,083          73.7     25.2    1,257     52.0        46.8   3,308   4.5    94.0   1,208   58.7   40.5   4,142    77.5      22.2
                                                Oxacillin                 23,523          0        100     1,995     0.2         99.8   3,652   0      100    1,360   0      100    4,268    0         100
                                                Teicoplanin               NT              NT       NT      NT        NT          NT     3,466   100    0      1,039   99.7   0.3    3,214    100       0
                                                Vancomycin                23,135          100      0       1,836     100         0      3,507   100    0      1,274   100    0      3,873    100       0
  *Staphylcoccus* species, coagulase-negative                                                                                                                                                          
                                                Ampicillin                16,288          5.7      94.3    3,533     6.3         93.7   2,142   10.6   89.4   4,075   8.1    91.9   \<10     NA        NA
                                                Cefepime                  991             11.8     88.1    \<10      NA          NA     116     0      100    625     11.0   73.1   \<10     NA        NA
                                                Cefotaxime                5,538           17.7     82.3    240       17.9        82.1   335     16.7   83.3   625     37.4   62.4   174      28.7      69.0
                                                Ceftriaxone               3,471           14.8     84.8    116       22.4        77.6   512     11.7   88.3   412     25.0   74.8   \<10     NA        NA
                                                Ciprofloxacin             18,829          40.2     58.3    5,366     44.4        54.7   5,102   42.7   54.0   6,197   29.5   67.6   198      44.4      53.0
                                                Gentamicin                27,248          51.5     38.1    5,571     40.6        47.3   5,241   33.8   60.7   6,848   41.5   51.7   9,422    46.8      51.5
                                                Oxacillin                 35,135          15.8     84.2    9,172     20.6        79.4   5,961   15.2   84.8   7,442   18.6   81.4   9,884    30.1      69.9
                                                Teicoplanin               NT              NT       NT      NT        NT          NT     5,797   93.7   2.4    5,096   95.6   0.7    7,670    84.6      3.1
                                                Vancomycin                34,424          100      0       8,239     100         0      5,937   100    0      6,953   100    0      8,300    100       0
  *Staphylcoccus* species, coagulase-negative                                                                                                                                                          
  Oxacillin susceptible                         Ampicillin                2,582           35.7     64.3    638       34.6        65.4   437     51.7   48.3   824     39.6   60.4   \<10     NA        NA
                                                Cefepime                  117             100      0       NT        NT          NT     NT      NT     NT     \<10    NA     NA     NT       NT        NT
                                                Cefotaxime                978             99.5     0.2     42        100         0      56      100    0      128     100    0      54       92.6      0
                                                Ceftriaxone               523             98.3     0.4     26        100         0      59      100    0      103     100    0      \<10     NA        NA
                                                Ciprofloxacin             2,844           82.4     16.6    988       91.8        7.6    779     87.7   10.1   1,103   89.5   9.2    78       83.3      14.1
                                                Gentamicin                4,424           93.5     4.2     1,068     91.9        5.3    698     94.3   5.3    1,263   96.5   2.7    2,822    93.9      5.4
                                                Oxacillin                 5,565           100      0       1,886     99.9        0.1    904     100    0      1,383   100    0      2,980    100       0
                                                Teicoplanin               NT              NT       NT      NT        NT          NT     890     99.1   0.3    691     98.4   0.3    2,454    95.8      0.2
                                                Vancomycin                5,240           100      0       1,587     100         0      897     100    0      981     100    0      2,467    100       0
  *Staphylcoccus* species, coagulase-negative                                                                                                                                                          
  Oxacillin resistant                           Ampicillin                13,706          0.1      99.9    2,895     0           100    1,705   0      100    3,251   0.2    99.8   \<10     NA        NA
                                                Cefepime                  874             0        99.9    \<10      NA          NA     116     0      100    624     10.9   73.2   \<10     NA        NA
                                                Cefotaxime                4,560           0.1      99.9    198       0.5         99.5   279     0      100    497     21.3   78.5   120      0         100
                                                Ceftriaxone               2,948           0        99.8    90        0           100    453     0.2    99.8   309     0.0    99.7   \<10     NA        NA
                                                Ciprofloxacin             15,985          32.7     65.8    4,378     33.7        65.3   4,323   34.7   61.9   5,094   16.5   80.2   120      19.2      78.3
                                                Gentamicin                22,824          43.3     44.7    4,503     28.5        57.3   4,543   24.5   69.2   5,585   29.1   62.8   6,600    26.6      71.3
                                                Oxacillin                 29,570          0        100     7,286     0           100    5,057   0      100    6,059   0      100    6,904    0         100
                                                Teicoplanin               NT              NT       NT      NT        NT          NT     4,907   92.7   2.8    4,405   95.1   0.8    5,216    79.3      4.5
                                                Vancomycin                29,184          100      0       6,652     100         0      5,040   100    0      5,972   100    0      5,833    100       0
  *Enterococcus faecalis*                                                                                                                                                                              
                                                Ampicillin                7,865           98.8     1.2     1,000     99.4        0.6    1,289   95.3   4.7    1,902   99.6   0.4    1,183    99.5      0.2
                                                Ciprofloxacin             3,311           56.9     38.7    625       45.3        50.4   1,159   64.0   31.1   2,012   39.7   39.5   559      78.5      17.0
                                                Gentamicin (HL Testing)   5,503           65.1     34.8    706       63.0        36.8   1,156   62.9   37.1   965     64.8   35.2   1,563    63.6      13.4
                                                Teicoplanin               NT              NT       NT      \<10      NA          NA     1,248   97.1   2.4    1,294   99.7   0.2    1,747    99.9      0.1
                                                Vancomycin                7,656           95.1     4.5     1,005     98.3        0.9    1,303   96.7   2.8    1,636   99.4   0.3    1,811    99.7      0.2
  *Enterococcus faecium*                                                                                                                                                                               
                                                Ampicillin                3,896           9.7      90.3    383       17.2        82.8   260     21.5   78.5   481     12.3   87.7   151      41.7      49.7
                                                Ciprofloxacin             1,846           5.3      92.5    221       10.9        85.5   234     10.3   77.4   591     6.9    73.9   66       21.2      39.4
                                                Gentamicin (HL Testing)   2,512           57.5     42.5    291       59.5        40.5   223     67.7   32.3   349     60.2   39.8   263      65.4      12.2
                                                Teicoplanin               23              8.7      87.0    \<10      NA          NA     234     86.3   13.7   517     97.9   2.1    266      99.6      0.4
  Vancomycin                                    4,066                     23.2            76.3     415     85.1      14.5        264    75.4    24.2   628    93.9    4.8    247    98.4     0.8       

^a^NCCLS breakpoints were used for all countries, except (CA-SFM) ^b^Not tested ^c^Not applicable if \<10 isolates were tested

###### 

*S. pneumoniae*, *S. pyogenes*, *S. agalactiae*, and Viridans group streptococci isolated from ICU patients during 2000--2002

                                                    United States   Canada   Italy   Germany   France^a^                                                                     
  -------------------------------- ---------------- --------------- -------- ------- --------- ----------- ------ ------ ------ ------ ------- ------ ------ ------- ------- ------
  *Streptococcus pneumoniae*       Amoxicillin      120             91.7     2.5     31        100         0      60     93.3   6.7    17      100    0      1,328   71.2    2.3
                                   Cefepime         22              90.9     4.5     25        60.0        12.0   66     90.9   7.6    NT^b^   NT     NT     \<10    NA^c^   NA
                                   Cefotaxime       1,571           82.2     6.3     145       93.8        0.7    108    93.5   4.6    63      100    0      1,181   77.1    0.8
                                   Ceftriaxone      2,373           88.3     3.2     145       91.7        0.7    145    91.7   3.4    29      100    0      544     80.1    0.6
                                   Clarithromycin   184             71.7     25.5    56        69.6        30.4   90     64.4   31.1   \<10    NA     NA     NT      NT      NT
                                   Erythromycin     3,029           67.9     30.5    539       78.5        20.8   313    69.6   28.1   405     88.6   9.4    1,567   59.0    38.8
                                   Levofloxacin     2,133           99.1     0.4     356       98.6        1.1    174    98.3   0.6    340     99.4   0.3    62      98.4    1.6
                                   Penicillin       3,096           51.5     20.2    325       59.1        7.1    198    77.3   7.6    102     96.1   2.0    1,387   45.5    17.9
                                   Vancomycin       2,865           100      \-^c^   271       100         \-     231    100    \-     190     100    \-     1,479   100     \-
  *Streptococcus pyogenes*                                                                                                                                                   
                                   Amoxicillin      NT              NT       NT      NT        NT          NT     NT     NT     NT     NT      NT     NT     58      100     0
                                   Cefepime         \<10            NA       NA      NT        NT          NT     NT     NT     NT     NT      NT     NT     NT      NT      NT
                                   Cefotaxime       32              100      \-      29        100         \-     \<10   NA     NA     11      100    \-     30      100     \-
                                   Ceftriaxone      75              100      \-      \<10      NA          NA     \<10   NA     NA     \<10    NA     NA     \<10    NA      NA
                                   Clarithromycin   19              84.2     5.3     \<10      NA          NA     17     88.2   11.8   NT      NT     NT     NT      NT      NT
                                   Erythromycin     118             92.4     6.8     102       81.4        11.8   59     74.6   23.7   63      84.1   11.1   170     82.9    14.7
                                   Levofloxacin     71              97.2     1.4     \<10      NA          NA     \<10   NA     NA     61      77.0   4.9    NT      NT      NT
                                   Penicillin       140             100      \-      97        100         \-     58     100    \-     64      100    \-     139     100     \-
                                   Vancomycin       121             100      \-      42        100         \-     12     100    \-     34      100    \-     162     100     \-
  *Streptococcus agalactiae*                                                                                                                                                 
                                   Amoxicillin      NT              NT       NT      NT        NT          NT     NT     NT     NT     NT      NT     NT     165     100     0
                                   Cefepime         28              100      \-      NT        NT          NT     \<10   NA     NA     NT      NT     NT     NT      NT      NT
                                   Cefotaxime       71              100      \-      17        100         \-     24     100    \-     50      100    \-     50      100     \-
                                   Ceftriaxone      184             100      \-      \<10      NA          NA     38     100    \-     37      100    \-     \<10    NA      NA
                                   Clarithromycin   21              81.0     9.5     \<10      NA          NA     21     71.4   28.6   NT      NT     NT     \<10    NA      NA
                                   Erythromycin     489             76.3     21.7    222       82.9        14.9   121    77.7   18.2   192     83.9   10.9   588     79.9    16.2
                                   Levofloxacin     333             97.9     1.2     \<10      NA          NA     51     98.0   0      180     91.1   1.7    173     99.4    0
                                   Penicillin       518             100      \-      226       100         \-     145    100    \-     184     100    \-     369     100     \-
                                   Vancomycin       463             100      \-      179       100         \-     143    100    \-     65      100    \-     526     100     \-
  *Streptococcus* viridans group                                                                                                                                             
                                   Amoxicillin      NT              NT       NT      NT        NT          NT     NT     NT     NT     NT      NT     NT     268     92.9    0.7
                                   Cefepime         23              95.7     4.3     NT        NT          NT     12     66.7   33.3   NT      NT     NT     NT      NT      NT
                                   Cefotaxime       434             83.6     11.1    101       92.1        4.0    31     90.3   9.7    75      97.3   2.7    56      94.6    0
                                   Ceftriaxone      678             87.3     7.7     130       89.2        3.8    99     81.8   18.2   40      97.5   2.5    \<10    NA      NA
                                   Clarithromycin   34              52.9     38.2    21        76.2        19.0   21     71.4   23.8   \<10    NA     NA     NT      NT      NT
                                   Erythromycin     959             57.2     37.7    289       71.6        23.2   192    64.6   32.8   796     88.1   9.2    626     59.9    31.6
                                   Levofloxacin     331             96.1     2.7     \<10      NA          NA     16     87.5   0      93      89.2   4.3    \<10    NA      NA
                                   Penicillin       1,047           63.7     6.2     303       79.2        0      61     78.7   8.2    \<10    NA     NA     452     69.0    3.1
  Vancomycin                       1,095            100             \-       276     100       \-          180    100    \-     277    100     \-     580    100     \-      

^a^NCCLS breakpoints were used for all countries, except France (CA-SFM) ^b^Not tested ^c^Breakpoints do not currently exist to interpret as S (susceptible) or R (resistant)

###### 

*Enterobacteriaceae* isolated from ICU patients during 2000--2002

                                                                  United States   Canada   Italy   Germany   France^a^                                                                      
  ------------------------------- ------------------------------- --------------- -------- ------- --------- ----------- ------ ------- ------ ------ ------- ------ ------ ------- ------- ------
  *Escherichia coli*              Cefepime                        10,356          98.1     1.5     207       98.1        1.9    1,426   98.1   1.4    2,830   98.6   1.2    4,358   98.9    0.6
                                  Cefotaxime                      9,086           96.5     2.2     3,231     96.3        2.5    1,748   94.5   3.8    5,828   97.8   1.8    9,362   98.8    0.6
                                  Ceftazidime                     14,574          95.3     3.0     4,438     97.7        1.6    2,548   94.7   3.7    3,924   97.9   1.6    9,164   97.8    1.2
                                  Ceftriaxone                     15,897          97.4     1.7     3,829     96.8        2.2    1,423   94.4   4.2    534     99.8   0.2    834     98.6    1.0
                                  Ciprofloxacin                   17,294          89.0     10.7    5,028     90.3        9.5    2,616   87.0   12.7   4,615   86.7   12.4   8,577   93.1    6.5
                                  Gentamicin                      20,581          92.4     6.5     6,654     92.8        5.3    2,650   92.2   6.6    4,825   94.3   5.2    9,442   95.4    4.2
                                  Imipenem                        15,353          100      0       3,386     100         0      2,254   100    0      5,172   100    0      8,994   100     0
                                  Levofloxacin                    14,920          88.2     11.6    776       85.1        13.9   496     86.5   13.3   3,137   88.2   11.0   NT^b^   NT      NT
                                  Piperacillin-tazobactam         13,573          93.1     3.6     4,305     95.1        2.4    1,879   95.8   2.4    5,637   93.6   3.4    7,255   95.4    1.1
                                  Trimethoprim-sulfamethoxazole   20,296          79.2     20.7    6,737     84.6        15.3   2,440   75.0   24.9   5,598   73.1   26.6   9,028   78.2    21.1
  *Klebsiella oxytoca*                                                                                                                                                                      
                                  Cefepime                        1,476           96.2     3.3     19        100         0      255     99.6   0      566     96.8   2.7    478     97.1    0.4
                                  Cefotaxime                      1,324           92.7     4.7     486       94.2        4.5    230     96.5   1.7    1,117   93.8   4.4    865     96.3    0.8
                                  Ceftazidime                     1,909           91.7     7.0     661       94.9        4.1    361     83.4   15.2   749     95.3   4.5    870     98.3    0.5
                                  Ceftriaxone                     2,035           89.9     6.6     536       93.8        2.8    197     81.7   2.0    83      97.6   0      79      87.3    2.5
                                  Ciprofloxacin                   2,226           92.5     5.9     745       96.0        3.0    368     96.7   3.0    905     90.1   7.8    815     94.5    4.8
                                  Gentamicin                      2,569           89.9     8.3     857       95.0        4.9    366     89.6   3.0    1,016   98.2   1.2    865     97.1    2.4
                                  Imipenem                        2,061           100      0       516       100         0      337     100    0      1,062   100    0      845     100     0
                                  Levofloxacin                    1,754           93.3     3.4     159       96.9        1.3    133     97.0   3.0    560     94.6   3.2    NT      NT      NT
                                  Piperacillin-tazobactam         1,801           82.7     13.9    624       91.2        7.1    313     81.8   11.2   1,113   78.9   18.1   742     88.3    10.4
                                  Trimethoprim-sulfamethoxazole   2,467           92.5     7.5     863       96.3        3.6    308     95.1   4.9    1,084   93.7   6.3    802     94.1    5.7
  *Klebsiella pneumoniae*                                                                                                                                                                   
                                  Cefepime                        7,276           95.8     3.4     98        100         0      552     93.5   5.6    1,068   95.7   3.5    840     95.6    3.0
                                  Cefotaxime                      6,243           91.0     6.1     1,411     97.9        1.5    850     76.7   16.4   2,414   93.1   6.0    1,553   94.4    1.9
                                  Ceftazidime                     9,597           88.5     10.1    2,238     97.5        2.2    1,142   69.8   28.5   1,665   90.0   8.2    1,591   92.5    5.2
                                  Ceftriaxone                     10,337          92.7     4.7     1,736     97.9        1.1    816     75.2   15.0   166     98.8   0.6    112     86.6    5.4
                                  Ciprofloxacin                   11,089          89.9     8.4     2,484     91.8        7.2    1,190   88.2   9.9    2,128   85.4   9.4    1,473   89.5    8.7
                                  Gentamicin                      13,012          91.6     7.0     2,906     96.7        2.9    1,211   81.4   14.5   2,065   91.6   6.1    1,553   97.1    2.7
                                  Imipenem                        10,263          100      0       1,766     100         0      1,066   100    0      2,351   100    0      1,567   100     0
                                  Levofloxacin                    9,626           91.0     6.4     485       93.4        3.7    287     78.4   21.3   1,228   92.6   4.4    NT      NT      NT
                                  Piperacillin-tazobactam         9,359           85.9     7.4     2,160     91.5        2.7    746     82.2   14.6   2,408   84.9   8.3    1,286   89.4    5.1
                                  Trimethoprim-sulfamethoxazole   12,641          88.6     11.1    2,924     92.8        7.1    1,103   82.0   18.0   2,324   82.2   17.2   1,443   88.2    10.9
  *Morganella morganii*                                                                                                                                                                     
                                  Cefepime                        566             95.9     2.3     \<10      NA          NA     121     97.5   2.5    262     94.7   5.0    412     96.1    0.2
                                  Cefotaxime                      499             78.8     8.4     156       91.0        3.8    144     74.3   6.3    437     86.7   3.9    678     81.1    5.9
                                  Ceftazidime                     715             73.6     17.3    256       79.7        10.9   213     75.6   15.0   313     84.0   7.7    673     78.6    8.0
                                  Ceftriaxone                     806             91.1     2.2     219       96.3        1.4    125     91.2   3.2    22      86.4   0      57      84.2    5.3
                                  Ciprofloxacin                   841             78.1     20.7    292       94.2        4.5    220     87.3   9.5    344     97.7   2.0    634     88.6    8.5
                                  Gentamicin                      967             84.0     14.1    329       94.5        4.6    222     90.1   8.6    378     96.8   2.1    679     95.6    3.4
                                  Imipenem                        784             100      0       196       100         0      206     100    0      402     100    0      649     99.8    0
                                  Levofloxacin                    725             78.1     19.3    42        95.2        4.8    55      90.9   9.1    251     98.0   1.6    NT      NT      NT
                                  Piperacillin-tazobactam         725             91.2     5.1     254       97.2        1.6    150     94.0   3.3    430     94.2   3.5    564     91.0    4.6
                                  Trimethoprim-sulfamethoxazole   936             75.1     24.7    329       91.8        8.2    193     79.8   20.2   435     93.1   6.9    627     83.9    14.2
  *Proteus mirabilis*                                                                                                                                                                       
                                  Cefepime                        1,964           98.2     1.0     20        100         0      395     87.6   11.4   599     99.2   0.8    736     99.0    0.1
                                  Cefotaxime                      1,794           99.1     0.5     295       99.7        0      441     69.4   23.4   1,209   98.8   0.7    1,503   99.5    0.1
                                  Ceftazidime                     2,684           98.0     1.1     463       99.4        0.2    630     86.0   9.4    821     98.5   1.0    1,505   99.3    0.2
                                  Ceftriaxone                     3,034           99.4     0.3     392       99.5        0      385     80.5   13.8   77      98.7   0      72      100     0
                                  Ciprofloxacin                   3,169           85.2     12.7    504       95.2        4.6    657     70.6   22.7   980     92.9   5.1    1,424   90.9    6.8
                                  Gentamicin                      3,796           91.5     7.7     698       92.6        7.2    670     61.6   37.2   992     92.9   5.9    1,509   91.3    7.9
                                  Imipenem                        2,850           100      0       367       100         0      580     100    0      1,020   100    0      1,319   100     0
                                  Levofloxacin                    2,825           87.8     10.5    94        100         0      202     61.9   34.7   688     96.5   2.3    \<10    NA^c^   NA
                                  Piperacillin-tazobactam         2,715           97.7     0.8     449       98.2        0.2    465     95.7   2.8    1,201   98.6   0.8    1,231   99.3    0.2
                                  Trimethoprim-sulfamethoxazole   3,706           85.2     14.7    708       89.4        10.6   615     61.6   38.0   1,159   80.8   19.1   1,411   79.7    18.6
  *Serratia marcescens*                                                                                                                                                                     
                                  Cefepime                        3,653           96.7     2.3     52        96.2        1.9    497     96.8   2.2    546     94.1   3.5    509     98.6    0.2
                                  Cefotaxime                      3,134           87.0     5.7     670       92.8        2.7    470     79.6   9.8    951     84.0   7.5    809     81.5    3.3
                                  Ceftazidime                     4,718           89.7     7.9     1,113     95.2        3.0    738     81.4   13.3   851     89.7   7.5    812     94.7    3.0
                                  Ceftriaxone                     4,710           90.5     4.6     846       95.4        1.7    444     86.7   6.3    160     45.6   0      115     77.4    4.3
                                  Ciprofloxacin                   5,006           91.0     6.7     1,292     85.0        11.7   757     83.5   4.5    978     72.6   12.4   787     78.9    10.5
                                  Gentamicin                      5,905           92.9     5.9     1,313     94.6        5.2    758     97.4   2.1    665     92.9   6.3    808     91.6    6.6
                                  Imipenem                        4,960           100      0       880       100         0      727     100    0      1,018   100    0      805     100     0
                                  Levofloxacin                    4,356           94.3     4.2     264       92.4        4.2    266     95.5   1.5    595     87.6   6.6    \<10    NA      NA
                                  Piperacillin-tazobactam         4,337           88.1     5.1     1,155     91.6        3.3    547     92.7   3.8    1,053   77.6   3.1    749     82.6    2.4
  Trimethoprim-sulfamethoxazole   5,697                           95.9            3.9      1,325   94.9      5.1         646    81.4    18.6   908    88.1    10.9   699    84.1    13.6    

^a^NCCLS breakpoints were used for all countries, except France (CA-SFM) ^b^Not tested ^c^Not applicable if \<10 isolates were tested

###### 

*P. aeruginosa* and *Acinetobacter* spp isolated from ICU patients during 2000--2002

                                                                  United States   Canada   Italy   Germany   France                                                                       
  ------------------------------- ------------------------------- --------------- -------- ------- --------- -------- ------- ------- ------ ------- ------- ------ ------ ------- ------ ------
  *Acinetobacter species*         Cefepime                        5,162           43.8     40.2    97        67.0     23.7    475     17.9   73.7    623     74.2   10.8   857     28.0   40.3
                                  Cefotaxime                      3,830           23.3     49.9    705       36.7     34.9    555     11.0   78.7    1,254   34.9   24.6   671     15.4   38.7
                                  Ceftazidime                     5,954           42.2     40.8    1,162     70.8     22.9    692     25.6   68.5    988     66.7   14.5   1,106   34.9   35.5
                                  Ceftriaxone                     4,709           16.3     55.9    874       32.4     28.7    452     8.8    72.6    104     42.3   11.5   81      9.9    51.9
                                  Ciprofloxacin                   5,808           39.7     58.0    1,156     72.1     25.9    686     21.1   76.7    1,126   74.8   22.9   1,038   37.7   61.2
                                  Gentamicin                      6,618           47.2     47.2    1,185     72.8     22.8    768     23.3   72.4    979     82.0   14.1   936     49.3   43.5
                                  Imipenem                        6,006           87.0     7.5     918       95.8     1.9     569     77.9   19.0    1,253   96.2   3.4    1,088   93.8   3.8
                                  Levofloxacin                    5,099           43.8     52.2    489       61.1     25.6    295     13.9   75.3    840     82.0   10.5   NT^b^   NT     NT
                                  Meropenem                       2,154           66.3     26.5    348       93.7     4.9     455     74.5   13.6    1,024   96.0   3.4    147     68.0   28.6
                                  Piperacillin                    4,658           35.4     45.9    959       66.5     19.5    635     19.5   69.9    1,171   59.7   12.9   805     35.0   50.3
                                  Piperacillin-tazobactam         3,429           53.6     28.5    903       70.7     23.1    425     35.1   46.4    1,225   81.8   7.5    878     74.5   10.5
                                  Trimethoprim-sulfamethoxazole   5,697           51.4     48.4    1,155     74.8     25.2    750     44.1   55.7    1,234   83.6   15.6   93      45.2   52.7
  *Pseudomonas aeruginosa*                                                                                                                                                                
                                  Cefepime                        20,220          72.5     12.4    371       73.3     12.4    5,056   58.9   28.9    3,483   80.3   7.8    7,967   52.6   16.2
                                  Cefotaxime                      11,283          9.2      50.4    1,836     13.3     47.5    4,181   6.0    70.7    2,689   7.7    52.2   NT      NT     NT
                                  Ceftazidime                     26,353          71.2     17.4    6,036     73.7     13.4    7,640   56.7   31.3    5,141   76.2   14.9   8,547   70.2   14.9
                                  Ceftriaxone                     14,066          12.1     56.4    2,847     11.3     59.7    3,383   8.4    70.4    154     26.6   7.8    NT      NT     NT
                                  Ciprofloxacin                   26,700          62.8     33.1    5,924     67.2     30.2    7,388   58.4   38.8    4,746   68.6   24.4   8,560   55.3   40.6
                                  Gentamicin                      29,268          69.4     21.5    5,951     72.2     15.9    7,522   52.2   41.7    3,913   74.0   14.3   7,327   44.0   46.1
                                  Imipenem                        26,076          73.5     22.1    3,775     77.9     18.2    7,057   59.7   27.8    4,412   70.5   19.0   8,575   69.5   21.4
                                  Levofloxacin                    21,059          62.7     31.7    713       56.8     33.5    2,427   44.9   51.0    2,953   68.0   23.9   NT      NT     NT
                                  Meropenem                       7,540           76.0     18.2    1,266     80.3     14.5    4,082   57.3   32.7    4,351   77.8   13.8   1,818   81.1   6.4
                                  Piperacillin                    22,855          77.7     22.2    5,520     80.9     18.8    7,004   63.1   36.7    4,554   81.7   14.1   8,454   64.1   24.1
                                  Piperacillin-tazobactam         21,848          85.5     14.4    4,190     91.0     9.0     5,252   77.7   22.0    4,746   85.8   10.7   8,256   69.6   15.9
  Trimethoprim-sulfamethoxazole   15,618                          3.6             96.4     4,283   4.0       96.0     7,054   4.1     95.8   3,375   4.2     95.8   NT     NT      NT     

^a^NCCLS breakpoints were used for all countries, except France (CA-SFM) ^b^NT = not tested

Results
=======

In vitro susceptibility data from over 220,000 isolates from ICUs in five countries over the period 2000--2002 were assimilated. The most frequent species isolated from infections in the ICU was *S. aureus*, being most common in three of the five countries (Table [1](#T1){ref-type="table"}). The oxacillin resistance rates among *S. aureus* varied markedly across countries from 19.7% in Canada to 59.5% in Italy. *E. coli* (7.7%--15.5%) and *P. aeruginosa* (10.8%--22.3%) were the most frequent Gram-negative organisms encountered. The Gram-positive genus *Enterococcus*, either as *E. faecalis, E. faecium* or non-speciated isolates accounted for \<10% of isolates in most countries with *E. faecalis* being the most common species \<4.3%. Community-acquired respiratory pathogens such as *Streptococcus pneumoniae* and *Haemophilus influenzae* were relatively uncommon in all five countries.

###### 

Incidence of pathogens isolated from ICU patients by country (%)

  United States                                    Canada   Italy                                         Germany   France                                                                                                                                                      
  ------------------------------------------------ -------- --------------------------------------------- --------- --------------------------------------------- -------- --------------------------------------------- -------- --------------------------------------------- --------
  *S. aureus*^a^                                   20.2     *S. aureus*^a^                                17.4      *P. aeruginosa*                               22.3     CNS                                           16.4     *S. aureus*^1^                                17.2
  CNS^b^                                           15.9     CNS                                           16.1      CNS                                           18.7     *S. aureus*^a^                                13.6     CNS                                           16.7
  *P. aeruginosa*                                  13.1     *E. coli*                                     12.6      *S. aureus*^a^                                18.1     *E. coli*                                     12.3     *E. coli*                                     15.5
  *E. coli*                                        9.2      *P. aeruginosa*                               11.3      *E. coli*                                     7.7      *P. aeruginosa*                               10.8     *P. aeruginosa*                               13.8
  *K. pneumoniae*                                  5.8      *Enterococcus* spp                            7.6       *E. faecalis*                                 3.9      *Enterococcus* spp                            7.4      S. pneumoniae                                 3.3
  *Enterococcus* spp                               5.4      *K. pneumoniae*                               5.5       *K. pneumoniae*                               3.5      *K. pneumoniae*                               5.4      *E. cloacae*                                  3.3
  *E. cloacae*                                     4.3      *E. cloacae*                                  4.2       *Enterococcus* spp                            3.3      *E. cloacae*                                  4.7      *E. faecalis*                                 3.0
  *E. faecalis*                                    3.7      *S. marcenscens*                              2.5       *E. cloacae*                                  2.6      E. faecalis                                   4.3      *K. pneumoniae*                               2.7
  *S. marcescens*                                  2.7      *H. influenzae*                               2.1       *S. marcescens*                               2.2      *P. mirabilis*                                2.6      *P. mirabilis*                                2.5
  *A. baumanii*                                    2.6      *E. faecalis*                                 2.1       *P. mirabilis*                                1.9      *K. oxytoca*                                  2.4      *Enterococcus* spp                            2.3
  *Enterobacteriaceae*^c^ (all species combined)   29.5     *Enterobacteriaceae* (all species combined)   33.0      *Enterobacteriaceae* (all species combined)   30.2     *Enterobacteriaceae* (all species combined)   36.0     *Enterobacteriaceae* (all species combined)   32.1
  Total (n)                                        26,624   Total (n)                                     54,445    Total (n)                                     34,609   Total (n)                                     48,385   Total (n)                                     62,459

^a^Proportion of *S. aureus* testing as MRSA was USA (52.3%), Canada (19.7%), Italy (59.4%), Germany (21.0%), and France (40.6%) ^b^CNS = Coagulase-negative staphylococci ^c^*Enterobacteriaceae* includes all species of genera occurring at \>0.1%

Tables [2](#T2){ref-type="table"},[3](#T3){ref-type="table"},[4](#T4){ref-type="table"},[5](#T5){ref-type="table"} show the antimicrobial susceptibility profiles of various Gram-positive and Gram-negative pathogens isolated from ICU patients against a range of relevant antimicrobials.

Specifically notable susceptibility patterns include the vancomycin susceptibility of all strains of staphylococci. Generally, there was a low proportion of vancomycin resistant *E. faecalis* \<5%, whereas vancomycin-resistant *E. faecium* was more prevalent ranging from 0.8% in France to 76.3% in the United States, with a wide inter-country variation (Table [2](#T2){ref-type="table"}). Penicillin resistance rates varied among *S. pneumoniae*, from 2.0% in Germany to 20.2% in the US with concurrent ceftriaxone resistance rates of 0% in Germany to 3.4% in Italy (Table [3](#T3){ref-type="table"}).

β-lactam activity was assessed by comparing four different cephalosporins and a β-lactam/β-lactamase inhibitor combination, piperacillin-tazobactam. Overall, the putative production of ESBLs among *E. coli* was low, \<6%, but ceftazidime resistance was reported at higher rates in *K. pneumoniae* and *S. marcescens*, with the highest rates seen in *M. morganii*, from 16.0% in Germany to 26.4% in the United States (Table [4](#T4){ref-type="table"}). Among the gram-negative organisms tested, ceftriaxone resistance rates were usually lower than ceftazidime, with the exception among *P. aeruginosa* and *Acinetobacter* spp. Cefepime, a fourth generation cephalosporin with anti-pseudomonal activity was also more active than ceftazidime (Table [5](#T5){ref-type="table"}). Against the *Enterobacteriaceae*, the β-lactam combination agent piperacillin-tazobactam was generally less active than ceftriaxone. These species showed a wide variation in fluoroquinolone susceptibility among both species and countries. Gentamicin resistance rates among the *Enterobacteriaceae* varied from 1.2% among *K. oxytoca* from Germany to 37.2% in *P. mirabilis* from Italy. Ciprofloxacin resistance rates among *E. coli* ranged from 6.5% in France to 12.7% in Italy. Variable fluoroquinolone resistance rates among *S. marcescens* were also demonstrated, with a range of resistance from 4.5% in Italy to 12.4% in Germany.

Discussion
==========

Data derived from international surveillance studies, such as those presented here, can provide a unique contemporary perspective on the susceptibility of commonly encountered organisms to commonly used antibiotics. Such surveillance systems play a crucial role in detecting emerging trends in resistance. Comparisons of these with data of other recent surveillance programs show the wide variations in susceptibility profiles and the need for ongoing unit-specific surveys.

In Germany the prevalence of resistance among gram-positive organisms remained comparatively low with an incidence of 21% MRSA. In 2000, Frank et al. reported that 96% of German isolates of *S. marcescens* and *M. morganii* were susceptible to ceftazidime, yet in this study we found 89.7% and 84.0%, respectively \[[@B9]\]. A similar decrease in activity was noted with *E. coli* and ciprofloxacin between the two studies, 91% in 1996--1997 compared with 86.7% in this study. Marked decreases in susceptibility of *P. aeruginosa* in Germany were also evident, with no agent showing \>85.8% susceptibility (piperacillin-tazobactam) compared with most agents having 85%--94% susceptibility in 1996--1997. Changes of 15--20% have been reported with ceftazidime, imipenem, ciprofloxacin and meropenem, while piperacillin-tazobactam has shown the smallest decrease in susceptibility with \<6% over the 4-year period. Piperacillin plus or minus tazobactam and cefepime were the most active agents, based on susceptibility, against *P. aeruginosa* in Germany. Conversely, ceftriaxone and imipenem were the most active agents, based on susceptibility, against *Klebsiella* spp., which account for almost 8% of ICU isolates.

Staphylococcal species from French ICU isolates showed a high proportion of oxacillin resistance, 40.6% and 69. 9% of *S. aureus* and coagulase-negative staphylococci spp., respectively. *S. pneumoniae* showed penicillin resistance of 17.9%, higher than the other four countries, although the activity of third-generation cephalosporins, ceftriaxone and cefotaxime, showed only 0.6% and 0.8% resistance, respectively. Despite a lower ceftazidime susceptibility breakpoint compared to NCCLS standards (MIC 4 μg/ml instead of 8 μg/ml) putative ESBL expression were slightly lower in France than in Germany in 2000--2002. Ceftazidime non-susceptibility rates among *E. coli*, *K. oxytoca*, and *P. mirabilis* were ≤ 2.2%; however, ceftazidime non-susceptibility rates among *K. pneumoniae*, *M. morganii* and *S. marcescens* were 7.5%, 21.4%, and 5.3%, respectively. Imipenem was active against all *Enterobacteriaceae*. Against *P. aeruginosa* and *Acinetobacter* spp., imipenem resistance rates were 21.4% and 3.8%, respectively. Previously, a lower imipenem resistance of 24% among French isolates of *P. aeruginosa* was reported \[[@B7]\].

Among the Italian isolates of staphylococci, oxacillin resistance occurred in 59.4% of *S. aureus* and 84.8% of coagulase-negative isolates. This MRSA rate was similar to that reported by Frank et al. from bacteremic isolates in Italy; however, they reported an increase in MRSA from 25% to 55% over the period 1997 to 2001 \[[@B18]\]. Vancomycin resistance rates of 2.8% for *E. faecalis* and 24.2% for *E. faecium* are some of the highest rates recorded in Europe, although still modest compared to rates experienced in the United States; however, teicoplanin was more active with 2.4% and 13.7% of strains being resistant, respectively. Pneumococcal resistance to penicillin and erythromycin was 7.6% and 28.1%, respectively. The impact of alterations in penicillin-binding protein that reduce penicillin susceptibility have less effect on the activity of third-generation cephalosporins such as ceftriaxone with 3.4% and cefotaxime with 4.6% resistance, respectively. *S. pyogenes* was fully susceptible to penicillin; however, 11.8% of isolates were resistant to clarithromycin and 23.7% were resistant to erythromycin.

The proportion of ESBLs was slightly higher in Italy with *E. coli* showing ceftazidime non-susceptibility of 5.3%, whereas *K. pneumoniae* and *K. oxytoca* demonstrated 30.2% and 16.6% ceftazidime non-susceptibility, respectively. Fluoroquinolone resistance rates among the *Enterobacteriaceae*, using ciprofloxacin as a marker, varied from 3.0% for *K. oxytoca* to 22.7% for *P. mirabilis*, and 12.7% for *E. coli*. Thus, among *Enterobacteriaceae*, ciprofloxacin was generally less active than the third-generation cephalosporin, ceftriaxone. *P. aeruginosa* and *Acinetobacter* spp. strains from Italian ICUs demonstrated significant resistance rates. Isolates of *P. aeruginosa* showed resistance rates of \>28% for all agents tested except piperacillin-tazobactam. Thus empiric therapy for possible pseudomonal infections will require combination therapy. *Acinetobacter* spp. showed a similar lack of susceptibility except to imipenem and meropenem (19.0% and 13.6% resistant). An increase in fluoroquinolone resistance in *E. coli* and *K. pneumoniae* in bacteremic isolates from Italy was observed during 1997--2001, with rates of 26.7% and 24%, respectively \[[@B9]\]. An increase in ureidopenicillin resistance was noted in *P. aeruginosa* isolates in Italy from 30% to 37% in a 4-year period \[[@B9]\]. This study showed 22.0% piperacillin-tazobactam and 36.7% piperacillin resistance among ICU *P. aeruginosa* isolates.

In Canada oxacillin-resistance among *S. aureus* was noted in 19.7% and coagulase-negative staphylococci in 79.4%. Vancomycin resistance was reported among 0.9% and 14.5% of *E. faecalis* and *E. faecium*, respectively. The lowest rate of penicillin resistance in *S. pneumoniae* in this study was noted from Canada at 7.1%; however, clarithromycin resistance was 30.4%. Ceftriaxone showed 0.7% resistance whereas cefepime exhibited 12.0% resistance among pneumococci from the ICU.

Overall the susceptibility rates for Gram-negative isolates from Canadian ICUs were higher than those in the other four countries examined. A low rate of ESBLs was reported, but there was variable activity of piperacillin-tazobactam which showed \>9% resistance among *Klebsiella* spp. and *S. marcescens* tested. The rate of fluoroquinolone resistance was similar to those of other countries with *E. coli* showing 13.9% levofloxacin resistance. Among *Enterobacteriaceae*, \<10% of most species were resistant to third-generation cephalosporins tested with the exception of ceftazidime and *M. morganii*. Resistance among *P. aeruginosa* and *Acinetobacter* spp. was generally lower than in other countries apart from Germany. Only piperacillin-tazobactam showed reliable activity against *P. aeruginosa* (9% resistant), while resistance to all other agents was \>19%. *Acinetobacter* spp. remained susceptible to only the carbapenems, imipenem and meropenem.

Comparison of the data from Canadian isolates with those from the United States shows some significant differences. This demonstrates the limitations of pooling Canadian and United States data since the differences between the two regions, such as the rate of MRSA, may have some impact on empiric therapy. Data from the NNIS system has previously reported an increasing trend towards resistance within ICUs in the United States \[[@B19]\]. Oxacillin resistance among staphylococci from ICUs in the United States was 52.3% and 84.2% for *S. aureus* and coagulase-negative species, respectively.

This value is identical to that of *S. aureus* and very similar to the CNS data reported by the 1999 NNIS system. The NNIS highlighted a 37% increase in MRSA over the period 1994--98 to 1999, but only a 2% increase among CNS strains \[[@B4]\]. Vancomycin resistance in the United States was observed in 4.5% of *E. faecalis*; however, over 76% *E. faecium* were vancomycin non-susceptible.

Although streptococci are uncommon ICU pathogens they can be rapidly invasive and possibly fatal unless adequate therapeutic approaches are adopted. *S. pneumoniae* in the United States has acquired a range of resistance mechanisms with resistance to penicillin and the macrolides, clarithromycin and erythromycin, being common, 20.2% and 25.5%--30.5% respectively. The newer generation cephalosporins, ceftriaxone, cefotaxime and cefepime showed good activity against pneumococci, 3.2%, 6.3% and 4.5% resistant, respectively. Less than 1.0% of isolates were resistant to levofloxacin. These data are similar to other recent reports \[[@B20]\].

For *Enterobacteriaceae* which account for approximately 30% of all isolates from ICU infections, the incidence of putative ESBLs was low in *E. coli*, 4.7% but ceftazidime non-susceptibility was higher in *K. oxytoca* 8.3%,*K. pneumoniae* 11.5%,*S. marcescens* 10.3% and *M. morganii* 26.4%. These data are consistent with other recent reports \[[@B21]\]. Fluoroquinolone resistance was observed in all *Enterobacteriaceae* tested, in the US for example, resistance rates were as follows, using ciprofloxacin as a marker: *E. coli* 10.7%, *K. oxytoca* 5.9%, *K. pneumoniae* 8.4%, *M. morganii* 20.7%, *P. mirabilis* 12.7% and *S. marcescens* 6.7%. These data show increased fluoroquinolone resistance compared with recent reports \[[@B21]\]. Jones et al. previously reported susceptibility data on ICU pathogens isolated over the period 1998--2001 \[[@B22]\].

Specifically, enteric bacteria showed changes over this time. Fluoroquinolone resistance doubled among *E. coli* isolates from 3.3--5.5% to 10.8--11.4% \[[@B22]\]. This study showed a generally higher level of activity among third-generation cephalosporins than other reports \[[@B23]\], with ceftriaxone showing \<10% resistance rates against most species tested. Piperacillin-tazobactam showed less consistent activity with some species being \>14% resistant, e.g. *Klebsiella* spp.,*P. aeruginosa*, and *Acinetobacter* spp. present significant therapeutic challenges in ICUs in the United States. With the exception of cefepime, all other tested antimicrobials demonstrated \>12% resistance to *P. aeruginosa*, many considerably higher. Piperacillin-tazobactam showed the next lowest resistance rate, 14.4%, with all other agents having rates of 17% or higher. Non-susceptibility to ciprofloxacin among *P. aeruginosa* was 37.2%, higher than in the Neuberger report. Sahm et al. reported a 10% increase in fluoroquinolone resistance among *P. aeruginosa* in the United States, whereas resistance emerged more slowly with the other classes of antimicrobials tested \[[@B12]\]. *Acinetobacter* infections continue to present significant therapeutic challenges due to the extensive resistance mechanisms demonstrated by the \>25% resistance shown in Table [5](#T5){ref-type="table"}. Only imipenem has any reliable activity against *Acinetobacter* spp. with an 87% susceptibility rate.

There are several implications of these data. It is essential that local surveillance programs be maintained in each country\'s ICU setting. The local data are vital to the formulary committees as they select appropriate agents to treat infections. There are clear differences among the five countries studied in this report. Although the predominant pathogens are similar, ongoing surveillance is essential to detect the emergence of resistant species. It is clear that certain classes of compounds are losing activity against the ICU pathogens tested. For example, the fluoroquinolones have reduced susceptibility among many Gram-negative species as well as staphylococci; however, the newer class members have enhanced activity against pneumococci. Advanced-generation cephalosporins have variable activity, with ceftriaxone showing consistently good activity against the *Enterobacteriaceae* and some staphylococci. Ceftazidime has lost potency due to the emergence of ESBL enzymes and also has diminished activity against *P. aeruginosa*. Piperacillin-tazobactam is generally active against *P. aeruginosa* in ICUs. The aminoglycoside, gentamicin has shown continued activity against most *Enterobacteriaceae* in all five countries, and modest activity against *S. aureus* but not against CNS strains. The gentamicin susceptibility of *P. aeruginosa* ranged from 44.0% in France to 74.0% in Germany, whereas *Acinetobacter* spp *.* showed more variable gentamicin susceptibility varying from 23.3% in Italy to 82.0% in Germany. These local data should be considered when treating infections in the ICU.

Use of agents with anti-pseudomonal activity such as cefepime, piperacillin-tazobactam or the carbapenems should preferably be reserved for patient types or infections where this pathogen is present or risk factors exist, as per the ATS Community acquired-pneumonia guidelines \[[@B24]\]. A combination of a third-generation cephalosporin such as ceftriaxone with vancomycin may be appropriate for bloodstream infections based upon the NNIS etiology data from 1992--1999.

Conclusions
===========

The current study confirmed the emergence of fluoroquinolone resistance among various Gram-negative species and staphylococci, which may be increasing due to the heightened use of these drugs; however the reported ESBL rates among *Enterobacteriaceae* was lower than noted in other studies and appeared to be stable. The prevalence of MRSA, perhaps the most significant resistant hospital pathogen, varied among the five countries and appeared to be increasing. Parenteral cephalosporins such as ceftriaxone and cefotaxime remained quite active against *Enterobacteriaceae*. Up-to-date susceptibility data should be made available as rapidly as possible to physicians so that appropriate targeted empirical therapy can be instituted, this approach can assist in maintaining the activity of the current antimicrobials. While local surveillance studies remain crucial, national surveillance studies such as this can provide an invaluable data source to provide guidance in formulary decision-making.
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